Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. (NASDAQ: TXG) is a life science technology company focused on single cell and spatial biology, and this news page aggregates company-related announcements, research collaborations and financial updates. The company’s integrated research solutions include instruments, consumables and software that are used by academic and translational researchers and biopharmaceutical companies to study complex biological systems.
News about 10x Genomics often highlights developments in its technology platforms, such as new single cell instruments, assays and spatial workflows. Recent announcements have described launches and enhancements within the Chromium single cell portfolio, including instruments and assays designed to make high-performance single cell analysis more accessible and scalable. The company has also reported new capabilities on its Xenium spatial platform, including spatial multiomic workflows that enable simultaneous RNA and protein detection on tissue sections.
Another key theme in TXG news is large-scale research collaborations. 10x Genomics has announced partnerships with academic medical centers, cancer institutes, research consortia and nonprofit organizations to apply its single cell and spatial technologies in areas such as autoimmune disease, oncology, immuno-oncology and transplantation. These initiatives often involve generating high-resolution molecular maps of cells and tissues, linking them with clinical data and exploring potential diagnostic or clinical reporting frameworks.
Investors and researchers following TXG news will also find periodic financial results, preliminary revenue updates and participation in healthcare and investor conferences. Together, these items provide insight into the company’s product adoption, geographic reach, research impact and engagement with the broader scientific and investment communities. Users interested in 10x Genomics can use this page to review company press releases and related coverage over time.
10x Genomics (Nasdaq: TXG) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 12, 2026. A public conference call and live webcast for analysts and investors begins at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments and outlook. The earnings news release will be posted on the company's website prior to the call. Interested parties can access a live webcast of the fireside chat on the Investors section at https://investors.10xgenomics.com/. The webcast will be archived for replay for at least 45 days after the event.
Amcor (NYSE: AMCR) completed a 1-for-5 reverse stock split, effective with trading on a split-adjusted basis on January 16, 2026.
The split was approved by shareholders on November 6, 2025, and the memorandum of association amendment was filed on January 14, 2026. Amcor ordinary shares continue trading under AMCR on the NYSE with a new CUSIP G0250X149. CHESS Depositary Interests continue trading under AMC on a split-adjusted basis. Computershare is acting as exchange agent; registered U.S. shareholders and CDI holders have specified contact numbers for exchange questions. More details are available in Amcor's September 23, 2025 proxy and on its investor website.
10x Genomics (NASDAQ: TXG) announced a collaboration with Brigham & Women's Hospital on a blood‑based, single‑cell study of autoimmune diseases launched Jan 12, 2026. The study plans to enroll 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus and giant cell arteritis plus healthy controls, collecting peripheral blood at routine visits and pairing single‑cell Chromium Flex assays with longitudinal clinical data. The collaboration aims to identify immune signatures tied to disease activity, flare, remission and treatment response and to build a framework for a future clinical report. The program aligns with 10x's multi‑year effort, including a planned CLIA‑certified lab and other institutional partnerships.
10x Genomics (NASDAQ: TXG) announced a multi-year collaboration with Dana-Farber Cancer Institute to analyze tumor samples from hundreds of patients across major solid tumor types using single cell and spatial profiling. The initiative aims to identify biomarkers tied to treatment response, resistance and progression and to define a clinical reporting framework to support precision oncology. 10x also plans to establish a CLIA-certified laboratory to enable assay implementation, analytical validation and future diagnostic services using its Chromium Flex single cell assay and Xenium spatial platform.
10x Genomics (NASDAQ: TXG) and the Cancer Research Institute launched a multi-phase, AI-driven immuno-oncology initiative to generate high-resolution single cell and spatial data from more than 20,000 samples to map immune responses to cancer.
The project begins with a pilot to produce ~3,000 samples using 10x Chromium and Xenium to benchmark early AI models, then expands to profile over 500 million cells using Chromium Flex across a broader lab network to inform immunotherapy and vaccine discovery.
10x Genomics (Nasdaq: TXG) reported preliminary, unaudited select results for Q4 and full-year 2025. Q4 revenue was approximately $166.0M (up 11% sequential, +1% YoY). FY2025 revenue was approximately $642.8M, or $598.7M excluding $44.1M of patent litigation settlement payments, a 2% decrease year‑over‑year on the adjusted basis. Instruments revenue fell sharply (FY instruments ~$56.8M, -39% YoY). Consumables grew to ~$507.2M for the year (+3% YoY). Cash and marketable securities were about $520M at year end. Company will present at the J.P. Morgan Healthcare Conference on Jan 12, 2026.
CareDx (Nasdaq: CDNA) and 10x Genomics (Nasdaq: TXG) launched ImmuneScape, a multiomics research program to map immune biology in transplant rejection and therapeutic response.
The collaboration will use 10x Xenium spatial and Chromium Flex single cell platforms to profile FFPE biopsy samples at cellular resolution, focusing on antibody-mediated rejection (AMR) and microvascular inflammation (MVI). Insights are intended to support future diagnostic development and to correlate tissue-level immune architecture with clinical outcomes, including response to anti-CD38 therapies.
10x Genomics (Nasdaq: TXG) announced that members of its management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. Pacific Time.
Investors and interested parties can watch a live webcast of the fireside chat via the company's Investors website at https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.
10x Genomics (Nasdaq: TXG), together with Garvan Institute and University of Tokyo, launched the Asia-Pacific Spatial Translational Research Alliance (ASTRA) on November 18, 2025 to build a pan-cancer spatial atlas using the Xenium spatial platform.
ASTRA will map cancer–immune interactions across 2,000 tumor samples, study ten major cancer types with custom Xenium panels, and create regional hubs and shared digital infrastructure to harmonize biospecimens and data across the Asia-Pacific. The consortium is supported by the ASPIRE program and will formally launch at the inaugural ASTRA Conference in Sydney on Nov 19–21, 2025.
10x Genomics (Nasdaq: TXG) said members of its management team will take part in a fireside chat at the Wolfe Research Healthcare Conference 2025 on Tuesday, November 18, 2025 at 11:20 a.m. ET.
Investors can watch a live webcast via the company’s Investors website and an archived replay will be available for at least 30 days after the event.
FAQ
What is the current stock price of 10X Genomics (TXG)?
What is the market cap of 10X Genomics (TXG)?
